-
公开(公告)号：US11253587B2
公开(公告)日：2022-02-22
申请号：US17218148
申请日：2021-03-30
IPC分类号： A61K39/12 , A61K39/00 , C12N7/00 , C07K14/005 , A61K39/21 , A61K39/215
摘要： The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.
-
公开(公告)号：US20210353741A1
公开(公告)日：2021-11-18
申请号：US17218148
申请日：2021-03-30
IPC分类号： A61K39/215 , C12N7/00
摘要： The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.
-
公开(公告)号：US20180289794A1
公开(公告)日：2018-10-11
申请号：US15795678
申请日：2017-10-27
摘要： The present disclosure provides compositions and methods useful for preventing and treating Zika virus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more Zika epitopes, such as, for example, from Zika envelope glycoprotein E and the Zika structural protein NS1 including variants thereof.
-
公开(公告)号：US20170112924A1
公开(公告)日：2017-04-27
申请号：US15348881
申请日：2016-11-10
发明人： Maura Ellen CAMPBELL
IPC分类号： A61K39/39 , A61K39/112 , A61K9/00 , A61K39/145 , A61K39/29 , A61K39/21 , A61K39/02
CPC分类号： A61K39/39 , A61K9/0019 , A61K9/127 , A61K9/19 , A61K39/00 , A61K39/0275 , A61K39/099 , A61K39/107 , A61K39/12 , A61K39/145 , A61K39/21 , A61K39/29 , A61K39/292 , A61K2039/55555 , A61K2039/55572 , C07H13/04 , C07H13/06 , C07H15/12 , C12N2760/16034 , C12N2760/16134 , C12N2760/16234 , Y02A50/484
摘要： In one aspect, the present disclosure provides compounds of formulae I and II. In another aspect, a compound of formula I or II is formulated into compositions with an antigen, optionally with a vesicle. In some embodiments, compositions are administered intramuscularly.
-
公开(公告)号：US20240123060A1
公开(公告)日：2024-04-18
申请号：US17621033
申请日：2020-06-19
发明人： David Evander Anderson , Zhi Hong , Qing Zhu
CPC分类号： A61K39/292 , A61K38/212 , A61K39/39 , A61P31/20 , A61P37/04 , A61K2039/55505
摘要： The present disclosure provides compositions and methods useful for inducing an immune response and overcoming immune tolerance in a subject suffering from Hepatitis B. As described herein, the compositions of the disclosure comprise HBsAg having S, Pre-S1 and Pre-S2 proteins, an aluminum phosphate adjuvant and interferon-α.
-
公开(公告)号：US20230149537A1
公开(公告)日：2023-05-18
申请号：US17995546
申请日：2021-04-06
发明人： Fabian GUSOVSKY , Lynn HAWKINS , Sally ISHIZAKA , David Evander ANDERSON , Anne-Catherine FLUCKIGER
IPC分类号： A61K39/215 , A61P31/14
CPC分类号： A61K39/215 , A61P31/14 , A61K2039/5258
摘要： Provided herein are vaccines including coronavirus antigens and E6020, as well as methods of mitigation of coronavirus infection by administering those vaccines.
-
公开(公告)号：US11248026B2
公开(公告)日：2022-02-15
申请号：US15683355
申请日：2017-08-22
IPC分类号： A61K39/12 , A61P31/22 , C07K14/005 , A61K39/245 , A61K39/00
摘要： The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
-
公开(公告)号：US20200376113A1
公开(公告)日：2020-12-03
申请号：US16888398
申请日：2020-05-29
IPC分类号： A61K39/245 , C07K14/005 , A61P35/00 , C12N7/00
摘要： The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM), e.g., compositions comprising virus-like particles (VLPs) comprising Moloney Murine leukemia virus (MMLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with GM-CSF, which, at dose of at least 10 μg gB/pp65Gag, reverse dysregulation of anti-HCMV immunity in GBM patients.
-
公开(公告)号：US09777043B2
公开(公告)日：2017-10-03
申请号：US14357423
申请日：2012-11-09
IPC分类号： C07K14/00 , C07K14/005 , A61K39/245 , A61K39/00
CPC分类号： C07K14/005 , A61K39/245 , A61K2039/5258 , A61K2039/70 , C07K2319/00 , C07K2319/03 , C12N2710/16134 , C12N2740/13023 , C12N2760/20234
摘要： The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
-
公开(公告)号：US20220233682A1
公开(公告)日：2022-07-28
申请号：US17573806
申请日：2022-01-12
IPC分类号： A61K39/215 , A61K39/21 , A61K39/205 , A61K39/39 , A61P31/14
摘要： The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include a spike protein from the Beta variant of SARS-Cov-2.
-
-
-
-
-
-
-
-
-
搜索结果
33 条记录 (耗时 0.024 秒)
